LR-90

• Description:

  LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes[1]. LR-90 is also used in the research of diabetic animal model[2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  COX

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Metabolic Disease; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/LR-90.html

• Purity:

  99.24

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C (NC1=CC=C (C=C1) OC (C) (C) C (O) =O) NC (C (Cl) =C2) =CC=C2CC3=CC=C (C (Cl) =C3) NC (NC4=CC=C (C=C4) OC (C) (C) C (O) =O) =O

• Molecular Formula:

  C35H34Cl2N4O8

• Molecular Weight:

  709.57

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Figarola JL, et al. Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes. 2007 Mar;56 (3) :647-55.|[2]Figarola JL, et al. LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia. 2008 May;51 (5) :882-91.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  245075-84-7